Agios Pharmaceuticals’s Return On Capital Employed Insights
According to Benzinga Pro, during Q4, Agios Pharmaceuticals (NASDAQ:AGIO) earned $36.53 million, a 144.68% increase from the preceding…
Agios Pharmaceuticals FY EPS $(4.23) Beats $(6.56) Estimate, Sales $14.24M Beat $14.18M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(4.23) per share which beat the analyst consensus estimate of $(6.56) by 35.52 percent. This is a 28.31 percent increase over losses of $(5.90) per share
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $33
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $48 to $33.
Europe Approves Agios Pharma’s Mitapivat For Adult Pyruvate Kinase Deficiency Patients
The European Commission has approved Agios Pharmaceuticals Inc’s (NASDAQ:AGIO) Pyrukynd (mitapivat) for PK deficiency in adult patients. Pyrukynd is a first-in-class,…
Agios Pharmaceuticals: Q3 Earnings Insights
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday’s Mid-Day Session
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.